Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2025. Verfasst von Hilla Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Internal Medicine, Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel. Hauptthemen laut MEDLINE: Ergocalciferols, Proteinuria, Dog Diseases, Hyperparathyroidism, Secondary. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European College of Veterinary Internal Medicine - Companion Animals (ECVIM-CA) Clinical Studies Fund Purina Institute Resident Research Award.
Abstract (Originalsprache)
Background
Renal secondary hyperparathyroidism (RHPT) is an inevitable consequence of chronic kidney disease (CKD). Paricalcitol might safely attenuate RHPT and proteinuria. Hypothesis/Objective Paricalcitol decreases parathyroid hormone (PTH) and proteinuria in dogs with CKD. Animals Thirteen dogs with naturally acquired CKD.
Methods
Placebo-controlled clinical trial. Dogs were randomly allocated to receive a placebo or paricalcitol (14 ng/kg/day) in a crossover design of 2, 12-week arms. Dogs were evaluated every 3 weeks. Associations between treatment, visit, and the outcome variables were assessed using generalized estimating equations.
Results
PTH decreased by 22% (95% CI, 7%–35%, p = 0.006) in the paricalcitol-treated dogs and increased by 18% (95% CI, 2%–37%, p = 0.022) in the placebo-treated dogs with each visit. FGF-23 at 12 weeks increased compared with baseline in the paricalcitol-treated (mean 6941 pg/mL, 95% CI, 1781–20 057 vs. 489 pg/mL, 95% CI, 188–1272, p < 0.001, respectively), but not in the placebo-treated dogs (696 pg/mL, 95% CI, 316–1531 vs. 955 pg/mL, 95% CI, 308–2963, p = 0.529). Urine protein-to-creatinine ratio at 12 weeks increased compared with baseline in the placebo-treated (0.8, 95% CI, 0.3–1.3 vs. 0.5, 95% CI, 0.2–0.9, p = 0.04, respectively), but not in the paricalcitol-treated dogs (0.6, 95% CI, 0.3–0.9 vs. 1.0, 95% CI, 0.1–1.8, p = 0.35). Ionized calcium was unchanged between baseline and 12 weeks in the paricalcitol- and placebo-treated groups (1.3 mmol/L, 95% CI, 1.29–1.35 and 1.34, 95% CI, 1.27–1.40 vs. 1.30, 95% CI, 1.25–1.35, p = 0.12 and 1.28, 95% CI, 1.24–1.32, p = 0.034, respectively). However, 7/13 dogs developed mild hypercalcemia. Adverse effects were not reported by the owners. Conclusion and Clinical Importance Paricalcitol attenuated RHPT and stabilized renal proteinuria in dogs with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Internal Medicine, Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
ORCID-Profile: Hilla Chen, Gilad Segev, Michal Mazaki-Tovi
Förderung
- European College of Veterinary Internal Medicine - Companion Animals (ECVIM-CA) Clinical Studies Fund Purina Institute Resident Research Award
Zitieren
APA
Chen, H., Segev, G., & Mazaki-Tovi, M. (2025). Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70063
Vancouver
Chen H, Segev G, Mazaki-Tovi M. Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70063
BibTeX
@article{Chen2025,
author = {Chen, Hilla and Segev, Gilad and Mazaki-Tovi, Michal},
title = {Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.70063}
}
EUVIMED